Form 4: Avalo Therapeutics CFO Sells Shares Under 10b5-1 Plan

Avalo Therapeutics' Chief Financial Officer, Christopher Ryan Sullivan, reported the sale of 18,606 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics, Inc., executed a Rule 10b5-1 trading plan on November 12, 2025.
• Under this plan, Sullivan sold 18,606 shares of common stock on May 7, 2026, at an average price of $24.12 per share.
• The sale was part of a series of transactions with prices ranging from $24.05 to $24.23.
• Following these transactions, Sullivan beneficially owns 423 shares of common stock.
• The filing also notes a stock option grant to Sullivan, with 18,606 options acquired on May 7, 2026, at an exercise price of $9.88, expiring August 13, 2034.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the significant sale of shares by the CFO, despite being executed under a Rule 10b5-1 plan.

Negatives

• The Chief Financial Officer sold a significant number of shares (18,606), which could be perceived negatively by the market.
• The sale occurred at a price significantly higher than the exercise price of the stock option ($24.12 average sale price vs. $9.88 option exercise price).

Risks

• The sale of shares by a key executive could signal a lack of confidence in the company's near-term prospects, potentially impacting investor sentiment.
• The Rule 10b5-1 plan, while providing an affirmative defense against insider trading allegations, still involves the disposal of company stock by management.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance. It solely reports on past transactions.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.
• The reported securities were sold in multiple transactions at prices ranging from $24.05 to $24.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
• The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions, especially under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors. These plans allow executives to sell shares during pre-determined periods, mitigating insider trading concerns. However, significant sales by C-suite executives can still influence market perception.

Stakeholder Impact

• Shareholders: May view the CFO's sale of shares negatively, potentially leading to short-term stock price pressure.
• Employees: May interpret the sale as a sign of executive confidence or lack thereof, depending on broader company performance.
• Creditors: Unlikely to be directly impacted by this transaction.

Key Dates

Recommendation

The filing reports a stock sale by the CFO under a 10b5-1 plan, which is a standard practice. While the sale itself is a negative signal, the plan's existence mitigates concerns about insider trading. Without further information on the company's performance or future prospects, a 'hold' recommendation is prudent, allowing investors to await more substantive news.

Keywords

Avalo Therapeutics, AVTX, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Christopher Ryan Sullivan, Chief Financial Officer, Beneficial Ownership, Stock Options